BioSpace News Archive

Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that Ryan Spencer, Chief Executive Officer, will participate in a virtual fireside chat at the H.C. Wainwright Virtual 22nd Annual Global Investment Conference

CooperCompanies (NYSE: COO), will participate in the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit, on September 23, 2020. Brian Andrews, Senior Vice President, Chief Financial Officer & Treasurer, will represent the Company in a virtual session scheduled to begin at 3:20 pm ET.

Bellicum Pharmaceuticals, Inc., a leader in developing novel, controllable cellular immunotherapies for cancers, announced equity inducement grants to three new employees consisting of an aggregate of 13,680 stock options.

Helix BioPharma Corp. (TSX:HBP) (“Helix” or the “Company”), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, today announced an update on the progress regarding the non-binding term sheet the Company received and previous announced on June 26, 2020

Perimeter Medical Imaging AI, Inc. (TSXV:PINK)(FSE:4PC), a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address areas of high unmet medical need, is providing an update on the status of the filing of its interim financial statements for its second quarter ending June 30, 2020.

Genomma Lab Internacional, S.A.B. de C.V. (BMV: LABB) (“Genomma Lab” or “the Company”), one of the leading pharmaceutical and personal care product companies in Mexico with an expanding international presence, announces the successful issuance of unsecured Mexican corporate bonds (Cebures) for a total amount of Ps. 1,000,000,000.00 (one billion Mexican pesos

Innovent Biologics, Inc. (Innovent) (HKEX: 01801), announced that the Phase I clinical study (CIBI112A101) of recombinant anti-interleukin 23p19 subunit antibody injection (IBI112) has completed the first healthy subject dosing in China.

Envista Holdings Corporation (NYSE: NVST) (“Envista”) today announced that the company will participate in the Baird 2020 Global Healthcare Conference on Wednesday, September 9, 2020.

Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, announced today that management will participate in the following upcoming investor conferences

Sparx Therapeutics, an emerging biopharmaceutical company specializing in developing multi-specific antibodies to treat solid tumors, today announced the appointment of Dr. Victor Wroblewski, a former Eli Lilly veteran, as a Senior VP and Head of Biology